ID   LCAT_HUMAN              Reviewed;         440 AA.
AC   P04180; Q53XQ3;
DT   20-MAR-1987, integrated into UniProtKB/Swiss-Prot.
DT   20-MAR-1987, sequence version 1.
DT   10-MAY-2017, entry version 181.
DE   RecName: Full=Phosphatidylcholine-sterol acyltransferase;
DE            EC=2.3.1.43 {ECO:0000269|PubMed:10222237, ECO:0000269|PubMed:10329423, ECO:0000269|PubMed:14636062, ECO:0000269|PubMed:19065001, ECO:0000269|PubMed:25727495, ECO:0000269|PubMed:26195816, ECO:0000269|PubMed:3458198};
DE   AltName: Full=Lecithin-cholesterol acyltransferase;
DE   AltName: Full=Phospholipid-cholesterol acyltransferase;
DE   Flags: Precursor;
GN   Name=LCAT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=3797244; DOI=10.1093/nar/14.23.9397;
RA   McLean J., Wion K., Drayna D., Fielding C., Lawn R.;
RT   "Human lecithin-cholesterol acyltransferase gene: complete gene
RT   sequence and sites of expression.";
RL   Nucleic Acids Res. 14:9397-9406(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 25-39; 172-182;
RP   269-280 AND 387-406, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=3458198; DOI=10.1073/pnas.83.8.2335;
RA   McLean J., Fielding C., Drayna D., Dieplinger H., Baer B., Kohr W.,
RA   Henzel W., Lawn R.;
RT   "Cloning and expression of human lecithin-cholesterol acyltransferase
RT   cDNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:2335-2339(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Nickerson D.A., Smith J.D., Fullerton S.M., Clark A.G., Stengard J.H.,
RA   Salomaa V., Boerwinkle E., Sing C.F., Weiss K.M.;
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 17-440.
RX   PubMed=2823898; DOI=10.1016/0167-4781(87)90066-2;
RA   Tata F., Chaves M.E., Markham A.F., Scrace G.D., Waterfield M.D.,
RA   McIntyre N., Williamson R., Humphries S.E.;
RT   "The isolation and characterisation of cDNA and genomic clones for
RT   human lecithin: cholesterol acyltransferase.";
RL   Biochim. Biophys. Acta 910:142-148(1987).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 13-440.
RX   PubMed=2823801; DOI=10.1016/0006-291X(87)91090-4;
RA   Rogne S., Skretting G., Larsen F., Myklebost O., Mevag B.,
RA   Carlson L.A., Holmquist L., Gjone E., Prydz H.;
RT   "The isolation and characterisation of a cDNA clone for human
RT   lecithin:cholesterol acyl transferase and its use to analyse the genes
RT   in patients with LCAT deficiency and fish eye disease.";
RL   Biochem. Biophys. Res. Commun. 148:161-169(1987).
RN   [10]
RP   PARTIAL PROTEIN SEQUENCE, AND DISULFIDE BONDS.
RX   PubMed=2880847;
RA   Yang C., Manoogian D., Pao Q., Lee F., Knapp R.D., Gotto A.M. Jr.,
RA   Pownall H.J.;
RT   "Lecithin:cholesterol acyltransferase. Functional regions and a
RT   structural model of the enzyme.";
RL   J. Biol. Chem. 262:3086-3091(1987).
RN   [11]
RP   GLYCOSYLATION AT ASN-44; ASN-108; ASN-296; ASN-408; THR-431 AND
RP   SER-433, STRUCTURE OF CARBOHYDRATES, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=7613477; DOI=10.1002/pro.5560040419;
RA   Schindler P.A., Settineri C.A., Collet X., Fielding C.J.,
RA   Burlingame A.L.;
RT   "Site-specific detection and structural characterization of the
RT   glycosylation of human plasma proteins lecithin:cholesterol
RT   acyltransferase and apolipoprotein D using HPLC/electrospray mass
RT   spectrometry and sequential glycosidase digestion.";
RL   Protein Sci. 4:791-803(1995).
RN   [12]
RP   CATALYTIC ACTIVITY, FUNCTION, SUBSTRATE SPECIFICITY, SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=8820107;
RA   Subbaiah P.V., Liu M.;
RT   "Comparative studies on the substrate specificity of
RT   lecithin:cholesterol acyltransferase towards the molecular species of
RT   phosphatidylcholine in the plasma of 14 vertebrates.";
RL   J. Lipid Res. 37:113-122(1996).
RN   [13]
RP   TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND CATALYTIC ACTIVITY.
RX   PubMed=10222237; DOI=10.1006/bbrc.1999.0601;
RA   Collet X., Francone O., Besnard F., Fielding C.J.;
RT   "Secretion of lecithin:cholesterol acyltransferase by brain neuroglial
RT   cell lines.";
RL   Biochem. Biophys. Res. Commun. 258:73-76(1999).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10329423; DOI=10.1006/bbrc.1999.0690;
RA   Kosek A.B., Durbin D., Jonas A.;
RT   "Binding affinity and reactivity of lecithin cholesterol
RT   acyltransferase with native lipoproteins.";
RL   Biochem. Biophys. Res. Commun. 258:548-551(1999).
RN   [15]
RP   FUNCTION IN HIGH-DENSITY LIPOPROTEIN PARTICLE REMODELING.
RX   PubMed=10722751; DOI=10.1074/jbc.275.12.9019;
RA   Clay M.A., Pyle D.H., Rye K.A., Barter P.J.;
RT   "Formation of spherical, reconstituted high density lipoproteins
RT   containing both apolipoproteins A-I and A-II is mediated by
RT   lecithin:cholesterol acyltransferase.";
RL   J. Biol. Chem. 275:9019-9025(2000).
RN   [16]
RP   SUBSTRATE SPECIFICITY, MUTAGENESIS OF GLU-173, FUNCTION, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=14636062; DOI=10.1021/bi035460u;
RA   Zhao Y., Wang J., Gebre A.K., Chisholm J.W., Parks J.S.;
RT   "Negative charge at amino acid 149 is the molecular determinant for
RT   substrate specificity of lecithin: cholesterol acyltransferase for
RT   phosphatidylcholine containing 20-carbon sn-2 fatty acyl chains.";
RL   Biochemistry 42:13941-13949(2003).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-44 AND ASN-296.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [18]
RP   ASSOCIATION WITH OBESITY.
RX   PubMed=17950106; DOI=10.1016/j.metabol.2007.06.022;
RA   Bajnok L., Seres I., Varga Z., Jeges S., Peti A., Karanyi Z.,
RA   Juhasz A., Csongradi E., Mezosi E., Nagy E.V., Paragh G.;
RT   "Relationship of endogenous hyperleptinemia to serum paraoxonase 1,
RT   cholesteryl ester transfer protein, and lecithin cholesterol
RT   acyltransferase in obese individuals.";
RL   Metabolism 56:1542-1549(2007).
RN   [19]
RP   ENZYME REGULATION, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=19065001; DOI=10.1194/jlr.M800584-JLR200;
RA   Hirsch-Reinshagen V., Donkin J., Stukas S., Chan J., Wilkinson A.,
RA   Fan J., Parks J.S., Kuivenhoven J.A., Lutjohann D., Pritchard H.,
RA   Wellington C.L.;
RT   "LCAT synthesized by primary astrocytes esterifies cholesterol on
RT   glia-derived lipoproteins.";
RL   J. Lipid Res. 50:885-893(2009).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 25-440, DISULFIDE BONDS,
RP   FUNCTION, CATALYTIC ACTIVITY, AND GLYCOSYLATION AT ASN-108; ASN-296
RP   AND ASN-408.
RX   PubMed=26195816; DOI=10.1194/jlr.M059873;
RA   Piper D.E., Romanow W.G., Gunawardane R.N., Fordstrom P.,
RA   Masterman S., Pan O., Thibault S.T., Zhang R., Meininger D.,
RA   Schwarz M., Wang Z., King C., Zhou M., Walker N.P.;
RT   "The high resolution crystal structure of human LCAT.";
RL   J. Lipid Res. 56:1711-1719(2015).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (8.69 ANGSTROMS) OF 45-421, CATALYTIC ACTIVITY,
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-108; ASN-296 AND ASN-408.
RX   PubMed=25727495; DOI=10.1038/ncomms7250;
RA   Glukhova A., Hinkovska-Galcheva V., Kelly R., Abe A., Shayman J.A.,
RA   Tesmer J.J.;
RT   "Structure and function of lysosomal phospholipase A2 and
RT   lecithin:cholesterol acyltransferase.";
RL   Nat. Commun. 6:6250-6250(2015).
RN   [22]
RP   VARIANT FED LEU-34.
RX   PubMed=1571050; DOI=10.1016/0006-291X(92)91772-I;
RA   Skretting G., Prydz H.;
RT   "An amino acid exchange in exon I of the human lecithin: cholesterol
RT   acyltransferase (LCAT) gene is associated with fish eye disease.";
RL   Biochem. Biophys. Res. Commun. 182:583-587(1992).
RN   [23]
RP   VARIANTS FED ILE-147 AND MET-371.
RX   PubMed=1737840; DOI=10.1172/JCI115612;
RA   Klein H.-G., Lohse P., Pritchard P.H., Bojanovski D., Schmidt H.,
RA   Brewer H.B. Jr.;
RT   "Two different allelic mutations in the lecithin-cholesterol
RT   acyltransferase gene associated with the fish eye syndrome. Lecithin-
RT   cholesterol acyltransferase (Thr123-->Ile) and lecithin-cholesterol
RT   acyltransferase (Thr347-->Met).";
RL   J. Clin. Invest. 89:499-506(1992).
RN   [24]
RP   VARIANT LCATD TRP-171.
RX   PubMed=2370048; DOI=10.1007/BF00193195;
RA   Taramelli R., Pontoglio M., Candiani G., Ottolenghi S., Dieplinger H.,
RA   Catapano A., Albers J., Vergani C., McLean J.;
RT   "Lecithin cholesterol acyl transferase deficiency: molecular analysis
RT   of a mutated allele.";
RL   Hum. Genet. 85:195-199(1990).
RN   [25]
RP   VARIANTS LCATD LYS-252 AND ILE-317.
RX   PubMed=1681161; DOI=10.1016/0140-6736(91)90665-C;
RA   Gotoda T., Yamada N., Murase T., Sakuma M., Murayama N., Shimano H.,
RA   Kozaki K., Albers J.J., Yazaki Y., Akanuma Y.;
RT   "Differential phenotypic expression by three mutant alleles in
RT   familial lecithin:cholesterol acyltransferase deficiency.";
RL   Lancet 338:778-781(1991).
RN   [26]
RP   VARIANT FED LYS-276.
RX   PubMed=1516702; DOI=10.1016/0014-5793(92)80795-I;
RA   Skretting G., Blomhoff J.P., Solheim J., Prydz H.;
RT   "The genetic defect of the original Norwegian lecithin:cholesterol
RT   acyltransferase deficiency families.";
RL   FEBS Lett. 309:307-310(1992).
RN   [27]
RP   VARIANT LCATD ILE-317.
RX   PubMed=1859405; DOI=10.1016/0006-291X(91)90129-U;
RA   Maeda E., Naka Y., Matozaki T., Sakuma M., Akanuma Y., Yoshino G.,
RA   Kasuga M.;
RT   "Lecithin-cholesterol acyltransferase (LCAT) deficiency with a
RT   missense mutation in exon 6 of the LCAT gene.";
RL   Biochem. Biophys. Res. Commun. 178:460-466(1991).
RN   [28]
RP   VARIANTS LCATD THR-117; TRP-159; PRO-233 AND MET-345, AND VARIANT
RP   CYS-182.
RX   PubMed=8432868; DOI=10.1172/JCI116248;
RA   Funke H., von Eckardstein A., Pritchard P.H., Hornby A.E.,
RA   Wiebusch H., Motti C., Hayden M.R., Dachet C., Jacotot B., Gerdes U.,
RA   Faergeman O., Albers J.J., Colleoni N., Catapano A., Frohlich J.,
RA   Assmann G.;
RT   "Genetic and phenotypic heterogeneity in familial lecithin:
RT   cholesterol acyltransferase (LCAT) deficiency. Six newly identified
RT   defective alleles further contribute to the structural heterogeneity
RT   in this disease.";
RL   J. Clin. Invest. 91:677-683(1993).
RN   [29]
RP   VARIANT LCATD THR-117, AND VARIANT CYS-182.
RX   PubMed=8318557; DOI=10.1016/0925-4439(93)90039-4;
RA   Hill J.S., O K., Wang X., Pritchard P.H.;
RT   "Lecithin:cholesterol acyltransferase deficiency: identification of a
RT   causative gene mutation and a co-inherited protein polymorphism.";
RL   Biochim. Biophys. Acta 1181:321-323(1993).
RN   [30]
RP   VARIANT LCATD HIS-164, AND CHARACTERIZATION OF VARIANT LCATD HIS-164.
RX   PubMed=7607641; DOI=10.1007/BF00214196;
RA   Steyrer E., Haubenwallner S., Hoerl G., Giessauf W., Kostner G.M.,
RA   Zechner R.;
RT   "A single G to A nucleotide transition in exon IV of the lecithin:
RT   cholesterol acyltransferase (LCAT) gene results in an Arg140 to His
RT   substitution and causes LCAT-deficiency.";
RL   Hum. Genet. 96:105-109(1995).
RN   [31]
RP   VARIANTS LCATD ARG-57 AND LEU-LEU-PRO-PRO-ALA-ALA-PRO-PHE-TRP-LEU-17
RP   INS.
RX   PubMed=7711728; DOI=10.1093/hmg/4.1.143;
RA   Wiebusch H., Cullen P., Owen J.S., Collins D., Sharp P.S., Funke H.,
RA   Assmann G.;
RT   "Deficiency of lecithin:cholesterol acyltransferase due to compound
RT   heterozygosity of two novel mutations (Gly33Arg and 30 bp ins) in the
RT   LCAT gene.";
RL   Hum. Mol. Genet. 4:143-145(1995).
RN   [32]
RP   VARIANTS FED GLN-34 AND GLN-159.
RX   PubMed=8620346; DOI=10.1161/01.ATV.16.2.294;
RA   Kuivenhoven J.A., Stalenhoef A.F., Hill J.S., Demacker P.N.,
RA   Errami A., Kastelein J.J., Pritchard P.H.;
RT   "Two novel molecular defects in the LCAT gene are associated with fish
RT   eye disease.";
RL   Arterioscler. Thromb. Vasc. Biol. 16:294-303(1996).
RN   [33]
RP   VARIANT LCATD SER-54.
RX   PubMed=8807342;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:1<79::AID-HUMU13>3.0.CO;2-O;
RA   Owen J.S., Wiebusch H., Cullen P., Watts G.F., Lima V.L.M., Funke H.,
RA   Assmann G.;
RT   "Complete deficiency of plasma lecithin-cholesterol acyltransferase
RT   (LCAT) activity due to a novel homozygous mutation (Gly-30-Ser) in the
RT   LCAT gene.";
RL   Hum. Mutat. 8:79-82(1996).
RN   [34]
RP   VARIANT LCATD ILE-29.
RX   PubMed=9007616; DOI=10.1007/BF02602958;
RA   Okubo M., Aoyama Y., Shio H., Albers J.J., Murase T.;
RT   "A novel missense mutation (Asn5-->Ile) in lecithin: cholesterol
RT   acyltransferase (LCAT) gene in a Japanese patient with LCAT
RT   deficiency.";
RL   Int. J. Clin. Lab. Res. 26:250-254(1996).
RN   [35]
RP   VARIANT FED CYS-123.
RX   PubMed=9261271; DOI=10.1161/01.ATV.17.7.1382;
RA   Blanco-Vaca F., Qu S.J., Fiol C., Fan H.Z., Pao Q.,
RA   Marzal-Casacuberta A., Albers J.J., Hurtado I., Gracia V., Pinto X.,
RA   Marti T., Pownall H.J.;
RT   "Molecular basis of fish-eye disease in a patient from Spain.
RT   Characterization of a novel mutation in the LCAT gene and lipid
RT   analysis of the cornea.";
RL   Arterioscler. Thromb. Vasc. Biol. 17:1382-1391(1997).
RN   [36]
RP   VARIANTS LCATD MET-37 AND SER-331.
RX   PubMed=9741700;
RA   Argyropoulos G., Jenkins A., Klein R.L., Lyons T., Wagenhorst B.,
RA   St Armand J., Marcovina S.M., Albers J.J., Pritchard P.H.,
RA   Garvey W.T.;
RT   "Transmission of two novel mutations in a pedigree with familial
RT   lecithin:cholesterol acyltransferase deficiency: structure-function
RT   relationships and studies in a compound heterozygous proband.";
RL   J. Lipid Res. 39:1870-1876(1998).
RN   [37]
RP   VARIANT LCATD ALA-298.
RX   PubMed=11423760; DOI=10.1159/000046001;
RA   Sessa A., Battini G., Meroni M., Daidone G., Carnera I.,
RA   Brambilla P.L., Vigano G., Giordano F., Pallotti F., Torri Tarelli L.,
RA   Calabresi L., Rolleri M., Bertolini S.;
RT   "Hypocomplementemic type II membranoproliferative glomerulonephritis
RT   in a male patient with familial lecithin-cholesterol acyltransferase
RT   deficiency due to two different allelic mutations.";
RL   Nephron 88:268-272(2001).
RN   [38]
RP   VARIANTS LCATD MET-345 AND VAL-406, AND VARIANT THR-232.
RX   PubMed=12957688; DOI=10.1016/S0021-9150(03)00241-7;
RA   Nanjee M.N., Stocks J., Cooke C.J., Molhuizen H.O., Marcovina S.,
RA   Crook D., Kastelein J.P., Miller N.E.;
RT   "A novel LCAT mutation (Phe382-->Val) in a kindred with familial LCAT
RT   deficiency and defective apolipoprotein B-100.";
RL   Atherosclerosis 170:105-113(2003).
RN   [39]
RP   VARIANT THR-232.
RX   PubMed=12966036; DOI=10.1093/hmg/ddg314;
RA   Morabia A., Cayanis E., Costanza M.C., Ross B.M., Flaherty M.S.,
RA   Alvin G.B., Das K., Gilliam T.C.;
RT   "Association of extreme blood lipid profile phenotypic variation with
RT   11 reverse cholesterol transport genes and 10 non-genetic
RT   cardiovascular disease risk factors.";
RL   Hum. Mol. Genet. 12:2733-2743(2003).
RN   [40]
RP   VARIANTS FED GLU-70 AND ALA-298, VARIANTS LCATD CYS-164; TRP-171;
RP   ASN-205; ASN-242; HIS-268; ILE-298 AND MET-333, AND VARIANTS PRO-115;
RP   THR-165 AND ARG-396.
RX   PubMed=15994445; DOI=10.1161/01.ATV.0000175751.30616.13;
RA   Calabresi L., Pisciotta L., Costantin A., Frigerio I., Eberini I.,
RA   Alessandrini P., Arca M., Bon G.B., Boscutti G., Busnach G.,
RA   Frasca G., Gesualdo L., Gigante M., Lupattelli G., Montali A.,
RA   Pizzolitto S., Rabbone I., Rolleri M., Ruotolo G., Sampietro T.,
RA   Sessa A., Vaudo G., Cantafora A., Veglia F., Calandra S.,
RA   Bertolini S., Franceschini G.;
RT   "The molecular basis of lecithin:cholesterol acyltransferase
RT   deficiency syndromes: a comprehensive study of molecular and
RT   biochemical findings in 13 unrelated Italian families.";
RL   Arterioscler. Thromb. Vasc. Biol. 25:1972-1978(2005).
RN   [41]
RP   VARIANT LCATD MET-333.
RX   PubMed=16051254; DOI=10.1016/j.atherosclerosis.2005.06.022;
RA   Idzior-Walus B., Sieradzki J., Kostner G., Malecki M.T., Klupa T.,
RA   Wesolowska T., Rostworowski W., Hartwich J., Walus M., Kiec A.D.,
RA   Naruszewicz M.;
RT   "Familial lecithin-cholesterol acyltransferase deficiency: biochemical
RT   characteristics and molecular analysis of a new LCAT mutation in a
RT   Polish family.";
RL   Atherosclerosis 185:413-420(2006).
RN   [42]
RP   VARIANT ARG-95, VARIANT LCATD HIS-164, AND CHARACTERIZATION OF VARIANT
RP   ARG-95.
RX   PubMed=16216249; DOI=10.1016/j.atherosclerosis.2005.08.038;
RA   Hoerl G., Kroisel P.M., Wagner E., Tiran B., Petek E., Steyrer E.;
RT   "Compound heterozygosity (G71R/R140H) in the lecithin:cholesterol
RT   acyltransferase (LCAT) gene results in an intermediate phenotype
RT   between LCAT-deficiency and fish-eye disease.";
RL   Atherosclerosis 187:101-109(2006).
RN   [43]
RP   VARIANTS THR-232 AND ARG-396.
RX   PubMed=16874701;
RA   Gigante M., Ranieri E., Cerullo G., Calabresi L., Iolascon A.,
RA   Assmann G., Morrone L., Pisciotta L., Schena F.P., Gesualdo L.;
RT   "LCAT deficiency: molecular and phenotypic characterization of an
RT   Italian family.";
RL   J. Nephrol. 19:375-381(2006).
RN   [44]
RP   VARIANTS 134-GLU-TYR-135 DELINS ASP-ASN; PHE-246; CYS-268 AND CYS-322,
RP   VARIANTS FED SER-99; PHE-338 AND CYS-347, CHARACTERIZATION OF VARIANTS
RP   134-GLU-TYR-135 DELINS ASP-ASN; PHE-246; CYS-268 AND CYS-322, AND
RP   CHARACTERIZATION OF VARIANTS FED SER-99; PHE-338 CYS-347 AND CYS-347.
RX   PubMed=21901787; DOI=10.1002/humu.21578;
RA   Holleboom A.G., Kuivenhoven J.A., Peelman F., Schimmel A.W., Peter J.,
RA   Defesche J.C., Kastelein J.J., Hovingh G.K., Stroes E.S.,
RA   Motazacker M.M.;
RT   "High prevalence of mutations in LCAT in patients with low HDL
RT   cholesterol levels in The Netherlands: identification and
RT   characterization of eight novel mutations.";
RL   Hum. Mutat. 32:1290-1298(2011).
CC   -!- FUNCTION: Central enzyme in the extracellular metabolism of plasma
CC       lipoproteins. Synthesized mainly in the liver and secreted into
CC       plasma where it converts cholesterol and phosphatidylcholines
CC       (lecithins) to cholesteryl esters and lysophosphatidylcholines on
CC       the surface of high and low density lipoproteins (HDLs and LDLs)
CC       (PubMed:10329423, PubMed:19065001, PubMed:26195816). The
CC       cholesterol ester is then transported back to the liver. Has a
CC       preference for plasma 16:0-18:2 or 18:O-18:2 phosphatidylcholines
CC       (PubMed:8820107). Also produced in the brain by primary
CC       astrocytes, and esterifies free cholesterol on nascent APOE-
CC       containing lipoproteins secreted from glia and influences cerebral
CC       spinal fluid (CSF) APOE- and APOA1 levels. Together with APOE and
CC       the cholesterol transporter ABCA1, plays a key role in the
CC       maturation of glial-derived, nascent lipoproteins. Required for
CC       remodeling high-density lipoprotein particles into their spherical
CC       forms (PubMed:10722751). {ECO:0000269|PubMed:10329423,
CC       ECO:0000269|PubMed:10722751, ECO:0000269|PubMed:14636062,
CC       ECO:0000269|PubMed:19065001, ECO:0000269|PubMed:26195816,
CC       ECO:0000269|PubMed:8820107}.
CC   -!- CATALYTIC ACTIVITY: Phosphatidylcholine + a sterol = 1-
CC       acylglycerophosphocholine + a sterol ester. {ECO:0000255|PROSITE-
CC       ProRule:PRU10037, ECO:0000269|PubMed:10222237,
CC       ECO:0000269|PubMed:10329423, ECO:0000269|PubMed:14636062,
CC       ECO:0000269|PubMed:19065001, ECO:0000269|PubMed:25727495,
CC       ECO:0000269|PubMed:26195816, ECO:0000269|PubMed:3458198,
CC       ECO:0000269|PubMed:8820107}.
CC   -!- ENZYME REGULATION: APOA1 is the most potent activator in plasma.
CC       Also activated by APOE, APOC1 and APOA4.
CC       {ECO:0000269|PubMed:19065001}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.97 mM for LDL {ECO:0000269|PubMed:10329423};
CC         KM=0.4 mM for HDL(2) {ECO:0000269|PubMed:10329423};
CC         KM=0.10 mM for HDL(3) {ECO:0000269|PubMed:10329423};
CC         Vmax=8.3 mmol/min/mg enzyme with LDL as substrate
CC         {ECO:0000269|PubMed:10329423};
CC         Vmax=0.58 mmol/min/mg enzyme with HDL(2) as substrate
CC         {ECO:0000269|PubMed:10329423};
CC         Vmax=2.0 mmol/min/mg enzyme with HDL(3) as substrate
CC         {ECO:0000269|PubMed:10329423};
CC         Note=Affinity for LDL is 2.3 to 4-fold lower than for HDL.
CC         Relative reactivities are 16% for HDL(3), 1.3% for HDL(2) and
CC         6.5% for LDL.;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10222237,
CC       ECO:0000269|PubMed:19065001, ECO:0000269|PubMed:3458198,
CC       ECO:0000269|PubMed:8820107}. Note=Secreted into blood plasma
CC       (PubMed:3458198, PubMed:8820107, PubMed:10222237). Produced in
CC       astrocytes and secreted into cerebral spinal fluid (CSF).
CC       {ECO:0000269|PubMed:10222237, ECO:0000269|PubMed:3458198,
CC       ECO:0000269|PubMed:8820107}.
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma (PubMed:3458198,
CC       PubMed:8820107, PubMed:10222237). Detected in cerebral spinal
CC       fluid (at protein level) (PubMed:10222237). Detected in liver
CC       (PubMed:3797244, PubMed:3458198). Expressed mainly in brain, liver
CC       and testes. {ECO:0000269|PubMed:10222237,
CC       ECO:0000269|PubMed:3458198, ECO:0000269|PubMed:3797244,
CC       ECO:0000269|PubMed:8820107}.
CC   -!- PTM: O- and N-glycosylated. O-glycosylation on Thr-431 and Ser-433
CC       consists of sialylated galactose beta 1-->3N-acetylgalactosamine
CC       structures. N-glycosylated sites contain sialylated triantennary
CC       and/or biantennary complex structures.
CC       {ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:7613477}.
CC   -!- DISEASE: Lecithin-cholesterol acyltransferase deficiency (LCATD)
CC       [MIM:245900]: A disorder of lipoprotein metabolism characterized
CC       by inadequate esterification of plasmatic cholesterol. Two
CC       clinical forms are recognized: complete LCAT deficiency and fish-
CC       eye disease. LCATD is generally referred to the complete form
CC       which is associated with absence of both alpha and beta LCAT
CC       activities resulting in esterification anomalies involving both
CC       HDL (alpha-LCAT activity) and LDL (beta-LCAT activity). It causes
CC       a typical triad of diffuse corneal opacities, target cell
CC       hemolytic anemia, and proteinuria with renal failure.
CC       {ECO:0000269|PubMed:11423760, ECO:0000269|PubMed:12957688,
CC       ECO:0000269|PubMed:15994445, ECO:0000269|PubMed:16051254,
CC       ECO:0000269|PubMed:16216249, ECO:0000269|PubMed:1681161,
CC       ECO:0000269|PubMed:1859405, ECO:0000269|PubMed:2370048,
CC       ECO:0000269|PubMed:7607641, ECO:0000269|PubMed:7711728,
CC       ECO:0000269|PubMed:8318557, ECO:0000269|PubMed:8432868,
CC       ECO:0000269|PubMed:8807342, ECO:0000269|PubMed:9007616,
CC       ECO:0000269|PubMed:9741700}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Fish-eye disease (FED) [MIM:136120]: A disorder of
CC       lipoprotein metabolism due to partial lecithin-cholesterol
CC       acyltransferase deficiency that affects only alpha-LCAT activity.
CC       FED is characterized by low plasma HDL and corneal opacities due
CC       to accumulation of cholesterol deposits in the cornea ('fish-
CC       eye'). {ECO:0000269|PubMed:1516702, ECO:0000269|PubMed:1571050,
CC       ECO:0000269|PubMed:15994445, ECO:0000269|PubMed:1737840,
CC       ECO:0000269|PubMed:21901787, ECO:0000269|PubMed:8620346,
CC       ECO:0000269|PubMed:9261271}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Levels of LCAT activity correlates inversely with
CC       leptin levels as well as with obesity for a wide range of BMI
CC       values.
CC   -!- SIMILARITY: Belongs to the AB hydrolase superfamily. Lipase
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Lecithin-cholesterol
CC       acyltransferase entry;
CC       URL="https://en.wikipedia.org/wiki/Lecithin-cholesterol_acyltransferase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04981; CAA28651.1; -; Genomic_DNA.
DR   EMBL; M12625; AAA59498.1; -; mRNA.
DR   EMBL; AY422210; AAR03499.1; -; Genomic_DNA.
DR   EMBL; BT009748; AAP88750.1; -; mRNA.
DR   EMBL; AC040162; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471092; EAW83190.1; -; Genomic_DNA.
DR   EMBL; BC014781; AAH14781.1; -; mRNA.
DR   EMBL; M26268; AAA59499.1; -; mRNA.
DR   EMBL; X06537; CAB56610.1; -; mRNA.
DR   EMBL; M17959; AAA59500.1; -; Genomic_DNA.
DR   CCDS; CCDS10854.1; -.
DR   PIR; A00571; XXHUN.
DR   RefSeq; NP_000220.1; NM_000229.1.
DR   UniGene; Hs.387239; -.
DR   PDB; 4X96; X-ray; 8.69 A; A/B/C/D=45-421.
DR   PDB; 4XWG; X-ray; 2.65 A; A=25-440.
DR   PDB; 4XX1; X-ray; 3.60 A; A/B/J=25-440.
DR   PDB; 5BV7; X-ray; 2.45 A; A=25-440.
DR   PDBsum; 4X96; -.
DR   PDBsum; 4XWG; -.
DR   PDBsum; 4XX1; -.
DR   PDBsum; 5BV7; -.
DR   ProteinModelPortal; P04180; -.
DR   SMR; P04180; -.
DR   BioGrid; 110123; 5.
DR   DIP; DIP-29620N; -.
DR   IntAct; P04180; 1.
DR   STRING; 9606.ENSP00000264005; -.
DR   BindingDB; P04180; -.
DR   ChEMBL; CHEMBL5942; -.
DR   SwissLipids; SLP:000000660; -.
DR   ESTHER; human-LCAT; PC-sterol_acyltransferase.
DR   iPTMnet; P04180; -.
DR   PhosphoSitePlus; P04180; -.
DR   UniCarbKB; P04180; -.
DR   BioMuta; LCAT; -.
DR   DMDM; 125993; -.
DR   MaxQB; P04180; -.
DR   PaxDb; P04180; -.
DR   PeptideAtlas; P04180; -.
DR   PRIDE; P04180; -.
DR   DNASU; 3931; -.
DR   Ensembl; ENST00000264005; ENSP00000264005; ENSG00000213398.
DR   GeneID; 3931; -.
DR   KEGG; hsa:3931; -.
DR   UCSC; uc002euy.2; human.
DR   CTD; 3931; -.
DR   DisGeNET; 3931; -.
DR   GeneCards; LCAT; -.
DR   H-InvDB; HIX0134431; -.
DR   HGNC; HGNC:6522; LCAT.
DR   HPA; HPA044767; -.
DR   MalaCards; LCAT; -.
DR   MIM; 136120; phenotype.
DR   MIM; 245900; phenotype.
DR   MIM; 606967; gene.
DR   neXtProt; NX_P04180; -.
DR   OpenTargets; ENSG00000213398; -.
DR   Orphanet; 79293; Familial LCAT deficiency.
DR   Orphanet; 79292; Fish-eye disease.
DR   PharmGKB; PA226; -.
DR   eggNOG; KOG2369; Eukaryota.
DR   eggNOG; ENOG410Y9CF; LUCA.
DR   GeneTree; ENSGT00390000004902; -.
DR   HOGENOM; HOG000238654; -.
DR   HOVERGEN; HBG017055; -.
DR   InParanoid; P04180; -.
DR   KO; K00650; -.
DR   OMA; THSTELC; -.
DR   OrthoDB; EOG091G07S3; -.
DR   PhylomeDB; P04180; -.
DR   TreeFam; TF313258; -.
DR   BRENDA; 2.3.1.43; 2681.
DR   Reactome; R-HSA-194223; HDL-mediated lipid transport.
DR   SABIO-RK; P04180; -.
DR   ChiTaRS; LCAT; human.
DR   GeneWiki; Lecithin%E2%80%94cholesterol_acyltransferase; -.
DR   GenomeRNAi; 3931; -.
DR   PRO; PR:P04180; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000213398; -.
DR   CleanEx; HS_LCAT; -.
DR   ExpressionAtlas; P04180; baseline and differential.
DR   Genevisible; P04180; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034186; F:apolipoprotein A-I binding; IPI:BHF-UCL.
DR   GO; GO:0004607; F:phosphatidylcholine-sterol O-acyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0034435; P:cholesterol esterification; IDA:UniProtKB.
DR   GO; GO:0042632; P:cholesterol homeostasis; IDA:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IDA:UniProtKB.
DR   GO; GO:0030301; P:cholesterol transport; IDA:MGI.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; IDA:UniProtKB.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; IEA:Ensembl.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0006656; P:phosphatidylcholine biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0046470; P:phosphatidylcholine metabolic process; IDA:UniProtKB.
DR   GO; GO:0006644; P:phospholipid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0090107; P:regulation of high-density lipoprotein particle assembly; IEA:Ensembl.
DR   GO; GO:0043691; P:reverse cholesterol transport; IDA:BHF-UCL.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   Gene3D; 3.40.50.1820; -; 1.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR003386; LACT/PDAT_acylTrfase.
DR   Pfam; PF02450; LCAT; 1.
DR   SUPFAM; SSF53474; SSF53474; 2.
DR   PROSITE; PS00120; LIPASE_SER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acyltransferase; Cholesterol metabolism;
KW   Complete proteome; Corneal dystrophy; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Lipid metabolism;
KW   Polymorphism; Reference proteome; Secreted; Signal;
KW   Steroid metabolism; Sterol metabolism; Transferase.
FT   SIGNAL        1     24       {ECO:0000269|PubMed:3458198}.
FT   CHAIN        25    440       Phosphatidylcholine-sterol
FT                                acyltransferase.
FT                                /FTId=PRO_0000017802.
FT   COMPBIAS    426    439       Pro-rich.
FT   ACT_SITE    205    205       Nucleophile.
FT                                {ECO:0000305|PubMed:26195816}.
FT   ACT_SITE    369    369       Charge relay system.
FT                                {ECO:0000305|PubMed:26195816}.
FT   ACT_SITE    401    401       Charge relay system.
FT                                {ECO:0000305|PubMed:26195816}.
FT   SITE        173    173       Determinant for substrate specificity.
FT                                {ECO:0000305|PubMed:14636062}.
FT   CARBOHYD     44     44       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:7613477}.
FT   CARBOHYD    108    108       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000244|PDB:4X96,
FT                                ECO:0000269|PubMed:26195816,
FT                                ECO:0000269|PubMed:7613477}.
FT   CARBOHYD    296    296       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000244|PDB:4X96,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:26195816,
FT                                ECO:0000269|PubMed:7613477}.
FT   CARBOHYD    408    408       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000244|PDB:4X96,
FT                                ECO:0000269|PubMed:26195816,
FT                                ECO:0000269|PubMed:7613477}.
FT   CARBOHYD    431    431       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:7613477}.
FT   CARBOHYD    433    433       O-linked (GalNAc...) serine.
FT                                {ECO:0000269|PubMed:7613477}.
FT   DISULFID     74     98       {ECO:0000244|PDB:4X96,
FT                                ECO:0000244|PDB:4XWG,
FT                                ECO:0000244|PDB:4XX1,
FT                                ECO:0000269|PubMed:26195816,
FT                                ECO:0000269|PubMed:2880847}.
FT   DISULFID    337    380       {ECO:0000244|PDB:4X96,
FT                                ECO:0000244|PDB:4XWG,
FT                                ECO:0000244|PDB:4XX1,
FT                                ECO:0000269|PubMed:26195816,
FT                                ECO:0000269|PubMed:2880847}.
FT   VARIANT      17     17       L -> LLLPPAAPFWL (in LCATD).
FT                                /FTId=VAR_004251.
FT   VARIANT      29     29       N -> I (in LCATD).
FT                                {ECO:0000269|PubMed:9007616}.
FT                                /FTId=VAR_039020.
FT   VARIANT      34     34       P -> L (in FED; dbSNP:rs121908051).
FT                                {ECO:0000269|PubMed:1571050}.
FT                                /FTId=VAR_004252.
FT   VARIANT      34     34       P -> Q (in FED).
FT                                {ECO:0000269|PubMed:8620346}.
FT                                /FTId=VAR_039021.
FT   VARIANT      37     37       T -> M (in LCATD).
FT                                {ECO:0000269|PubMed:9741700}.
FT                                /FTId=VAR_039022.
FT   VARIANT      54     54       G -> S (in LCATD).
FT                                {ECO:0000269|PubMed:8807342}.
FT                                /FTId=VAR_004253.
FT   VARIANT      57     57       G -> R (in LCATD).
FT                                {ECO:0000269|PubMed:7711728}.
FT                                /FTId=VAR_004254.
FT   VARIANT      70     70       V -> E (in FED; dbSNP:rs748427834).
FT                                {ECO:0000269|PubMed:15994445}.
FT                                /FTId=VAR_039023.
FT   VARIANT      95     95       G -> R (in a compound heterozygote
FT                                carrying H-164; intermediate phenotype
FT                                between LCATD and FED; reduction of
FT                                activity). {ECO:0000269|PubMed:16216249}.
FT                                /FTId=VAR_039024.
FT   VARIANT      99     99       W -> S (in FED; loss of activity).
FT                                {ECO:0000269|PubMed:21901787}.
FT                                /FTId=VAR_066862.
FT   VARIANT     115    115       S -> P. {ECO:0000269|PubMed:15994445}.
FT                                /FTId=VAR_039025.
FT   VARIANT     117    117       A -> T (in LCATD; dbSNP:rs28940886).
FT                                {ECO:0000269|PubMed:8318557,
FT                                ECO:0000269|PubMed:8432868}.
FT                                /FTId=VAR_004255.
FT   VARIANT     123    123       R -> C (in FED; dbSNP:rs140068549).
FT                                {ECO:0000269|PubMed:9261271}.
FT                                /FTId=VAR_039026.
FT   VARIANT     134    135       EY -> DN (in a patient with low HDL-
FT                                cholesterol levels; results in reduced
FT                                activity). {ECO:0000269|PubMed:21901787}.
FT                                /FTId=VAR_066863.
FT   VARIANT     147    147       T -> I (in FED; dbSNP:rs121908050).
FT                                {ECO:0000269|PubMed:1737840}.
FT                                /FTId=VAR_004256.
FT   VARIANT     159    159       R -> Q (in FED; dbSNP:rs768017317).
FT                                {ECO:0000269|PubMed:8620346}.
FT                                /FTId=VAR_039027.
FT   VARIANT     159    159       R -> W (in LCATD; dbSNP:rs28940887).
FT                                {ECO:0000269|PubMed:8432868}.
FT                                /FTId=VAR_004257.
FT   VARIANT     164    164       R -> C (in LCATD).
FT                                {ECO:0000269|PubMed:15994445}.
FT                                /FTId=VAR_039028.
FT   VARIANT     164    164       R -> H (in LCATD; also in a compound
FT                                heterozygote carrying R-95 with
FT                                intermediate phenotype between LCATD and
FT                                FED; loss of activity;
FT                                dbSNP:rs769485083).
FT                                {ECO:0000269|PubMed:16216249,
FT                                ECO:0000269|PubMed:7607641}.
FT                                /FTId=VAR_004258.
FT   VARIANT     165    165       A -> T. {ECO:0000269|PubMed:15994445}.
FT                                /FTId=VAR_039029.
FT   VARIANT     171    171       R -> W (in LCATD).
FT                                {ECO:0000269|PubMed:15994445,
FT                                ECO:0000269|PubMed:2370048}.
FT                                /FTId=VAR_004259.
FT   VARIANT     180    180       Y -> N (in LCATD; dbSNP:rs749740660).
FT                                /FTId=VAR_004260.
FT   VARIANT     182    182       R -> C (in dbSNP:rs387906300).
FT                                {ECO:0000269|PubMed:8318557,
FT                                ECO:0000269|PubMed:8432868}.
FT                                /FTId=VAR_004261.
FT   VARIANT     205    205       S -> N (in LCATD).
FT                                {ECO:0000269|PubMed:15994445}.
FT                                /FTId=VAR_039030.
FT   VARIANT     232    232       S -> T (in dbSNP:rs4986970).
FT                                {ECO:0000269|PubMed:12957688,
FT                                ECO:0000269|PubMed:12966036,
FT                                ECO:0000269|PubMed:16874701}.
FT                                /FTId=VAR_017030.
FT   VARIANT     233    233       L -> P (in LCATD; dbSNP:rs28942087).
FT                                {ECO:0000269|PubMed:8432868}.
FT                                /FTId=VAR_004262.
FT   VARIANT     242    242       K -> N (in LCATD).
FT                                {ECO:0000269|PubMed:15994445}.
FT                                /FTId=VAR_039031.
FT   VARIANT     246    246       V -> F (in a patient with low HDL-
FT                                cholesterol levels; the mutant is hardly
FT                                secreted and is catalytically inactive).
FT                                {ECO:0000269|PubMed:21901787}.
FT                                /FTId=VAR_066864.
FT   VARIANT     252    252       N -> K (in LCATD; dbSNP:rs121908049).
FT                                {ECO:0000269|PubMed:1681161}.
FT                                /FTId=VAR_004263.
FT   VARIANT     268    268       R -> C (in a patient with low HDL-
FT                                cholesterol levels; the mutant is hardly
FT                                secreted and is catalytically inactive;
FT                                dbSNP:rs745320775).
FT                                {ECO:0000269|PubMed:21901787}.
FT                                /FTId=VAR_066865.
FT   VARIANT     268    268       R -> H (in LCATD; dbSNP:rs780824776).
FT                                {ECO:0000269|PubMed:15994445}.
FT                                /FTId=VAR_039032.
FT   VARIANT     276    276       M -> K (in FED; dbSNP:rs121908054).
FT                                {ECO:0000269|PubMed:1516702}.
FT                                /FTId=VAR_004264.
FT   VARIANT     298    298       T -> A (in FED and LCATD).
FT                                {ECO:0000269|PubMed:11423760,
FT                                ECO:0000269|PubMed:15994445}.
FT                                /FTId=VAR_039033.
FT   VARIANT     298    298       T -> I (in LCATD).
FT                                {ECO:0000269|PubMed:15994445}.
FT                                /FTId=VAR_039034.
FT   VARIANT     317    317       M -> I (in LCATD; partially defective
FT                                enzyme; dbSNP:rs121908048).
FT                                {ECO:0000269|PubMed:1681161,
FT                                ECO:0000269|PubMed:1859405}.
FT                                /FTId=VAR_004265.
FT   VARIANT     322    322       R -> C (in a patient with low HDL-
FT                                cholesterol levels; reduced protein
FT                                secretion).
FT                                {ECO:0000269|PubMed:21901787}.
FT                                /FTId=VAR_066866.
FT   VARIANT     331    331       P -> S (in LCATD).
FT                                {ECO:0000269|PubMed:9741700}.
FT                                /FTId=VAR_039035.
FT   VARIANT     333    333       V -> M (in LCATD; dbSNP:rs776035233).
FT                                {ECO:0000269|PubMed:15994445,
FT                                ECO:0000269|PubMed:16051254}.
FT                                /FTId=VAR_039036.
FT   VARIANT     338    338       L -> F (in FED; results in reduced
FT                                protein secretion and activity).
FT                                {ECO:0000269|PubMed:21901787}.
FT                                /FTId=VAR_066867.
FT   VARIANT     345    345       T -> M (in LCATD; dbSNP:rs28940888).
FT                                {ECO:0000269|PubMed:12957688,
FT                                ECO:0000269|PubMed:8432868}.
FT                                /FTId=VAR_004266.
FT   VARIANT     347    347       R -> C (in FED; results in reduced
FT                                activity; dbSNP:rs202017590).
FT                                {ECO:0000269|PubMed:21901787}.
FT                                /FTId=VAR_066868.
FT   VARIANT     371    371       T -> M (in FED; dbSNP:rs121908053).
FT                                {ECO:0000269|PubMed:1737840}.
FT                                /FTId=VAR_004267.
FT   VARIANT     396    396       L -> R (in a patient with LCATD).
FT                                {ECO:0000269|PubMed:15994445,
FT                                ECO:0000269|PubMed:16874701}.
FT                                /FTId=VAR_039037.
FT   VARIANT     406    406       F -> V (in LCATD).
FT                                {ECO:0000269|PubMed:12957688}.
FT                                /FTId=VAR_039038.
FT   MUTAGEN     173    173       E->A: Increased activity towards PAPC.
FT                                Increased PAPC/POPC activity ratio.
FT                                {ECO:0000269|PubMed:14636062}.
FT   MUTAGEN     173    173       E->D: Little change in enzyme specific
FT                                activity nor in PAPC/POPC activity ratio.
FT                                {ECO:0000269|PubMed:14636062}.
FT   MUTAGEN     173    173       E->K: Decreased enzyme specific activity.
FT                                Increased PAPC/POPC activity ratio.
FT                                {ECO:0000269|PubMed:14636062}.
FT   MUTAGEN     173    173       E->L: Increased activity towards PAPC.
FT                                Increased PAPC/POPC activity ratio.
FT                                {ECO:0000269|PubMed:14636062}.
FT   MUTAGEN     173    173       E->Q: Decreased enzyme specific activity.
FT                                Increased PAPC/POPC activity ratio.
FT                                {ECO:0000269|PubMed:14636062}.
FT   CONFLICT    257    257       I -> H (in Ref. 8; CAB56610/AAA59499).
FT                                {ECO:0000305}.
FT   STRAND       49     52       {ECO:0000244|PDB:5BV7}.
FT   STRAND       60     63       {ECO:0000244|PDB:5BV7}.
FT   STRAND       82     86       {ECO:0000244|PDB:5BV7}.
FT   HELIX        88     91       {ECO:0000244|PDB:5BV7}.
FT   HELIX        95    103       {ECO:0000244|PDB:5BV7}.
FT   STRAND      105    107       {ECO:0000244|PDB:5BV7}.
FT   TURN        109    111       {ECO:0000244|PDB:5BV7}.
FT   STRAND      114    117       {ECO:0000244|PDB:5BV7}.
FT   STRAND      121    123       {ECO:0000244|PDB:5BV7}.
FT   TURN        125    128       {ECO:0000244|PDB:4XWG}.
FT   HELIX       131    134       {ECO:0000244|PDB:5BV7}.
FT   STRAND      135    137       {ECO:0000244|PDB:5BV7}.
FT   STRAND      142    145       {ECO:0000244|PDB:5BV7}.
FT   HELIX       146    153       {ECO:0000244|PDB:5BV7}.
FT   TURN        154    156       {ECO:0000244|PDB:5BV7}.
FT   TURN        160    162       {ECO:0000244|PDB:5BV7}.
FT   STRAND      163    165       {ECO:0000244|PDB:5BV7}.
FT   HELIX       174    176       {ECO:0000244|PDB:5BV7}.
FT   HELIX       178    195       {ECO:0000244|PDB:5BV7}.
FT   STRAND      199    204       {ECO:0000244|PDB:5BV7}.
FT   HELIX       206    217       {ECO:0000244|PDB:5BV7}.
FT   HELIX       220    226       {ECO:0000244|PDB:5BV7}.
FT   STRAND      227    234       {ECO:0000244|PDB:5BV7}.
FT   HELIX       242    248       {ECO:0000244|PDB:5BV7}.
FT   TURN        250    252       {ECO:0000244|PDB:5BV7}.
FT   TURN        255    257       {ECO:0000244|PDB:5BV7}.
FT   STRAND      270    272       {ECO:0000244|PDB:5BV7}.
FT   HELIX       274    276       {ECO:0000244|PDB:5BV7}.
FT   TURN        280    282       {ECO:0000244|PDB:5BV7}.
FT   STRAND      288    291       {ECO:0000244|PDB:5BV7}.
FT   STRAND      296    298       {ECO:0000244|PDB:5BV7}.
FT   HELIX       302    308       {ECO:0000244|PDB:5BV7}.
FT   HELIX       312    321       {ECO:0000244|PDB:5BV7}.
FT   TURN        322    327       {ECO:0000244|PDB:5BV7}.
FT   STRAND      335    350       {ECO:0000244|PDB:5BV7}.
FT   TURN        353    357       {ECO:0000244|PDB:5BV7}.
FT   STRAND      361    373       {ECO:0000244|PDB:5BV7}.
FT   HELIX       374    377       {ECO:0000244|PDB:5BV7}.
FT   HELIX       378    383       {ECO:0000244|PDB:5BV7}.
FT   STRAND      386    389       {ECO:0000244|PDB:5BV7}.
FT   STRAND      391    397       {ECO:0000244|PDB:5BV7}.
FT   HELIX       401    403       {ECO:0000244|PDB:5BV7}.
FT   TURN        404    406       {ECO:0000244|PDB:5BV7}.
FT   HELIX       408    419       {ECO:0000244|PDB:5BV7}.
FT   TURN        420    422       {ECO:0000244|PDB:5BV7}.
SQ   SEQUENCE   440 AA;  49578 MW;  B315EF118AA7A378 CRC64;
     MGPPGSPWQW VTLLLGLLLP PAAPFWLLNV LFPPHTTPKA ELSNHTRPVI LVPGCLGNQL
     EAKLDKPDVV NWMCYRKTED FFTIWLDLNM FLPLGVDCWI DNTRVVYNRS SGLVSNAPGV
     QIRVPGFGKT YSVEYLDSSK LAGYLHTLVQ NLVNNGYVRD ETVRAAPYDW RLEPGQQEEY
     YRKLAGLVEE MHAAYGKPVF LIGHSLGCLH LLYFLLRQPQ AWKDRFIDGF ISLGAPWGGS
     IKPMLVLASG DNQGIPIMSS IKLKEEQRIT TTSPWMFPSR MAWPEDHVFI STPSFNYTGR
     DFQRFFADLH FEEGWYMWLQ SRDLLAGLPA PGVEVYCLYG VGLPTPRTYI YDHGFPYTDP
     VGVLYEDGDD TVATRSTELC GLWQGRQPQP VHLLPLHGIQ HLNMVFSNLT LEHINAILLG
     AYRQGPPASP TASPEPPPPE
//
